PHILADELPHIA — The stiffness of breast tissue is increasingly recognized as an important factor explaining the onset of breast cancer. Stiffening induces molecular changes that promote cancerous behavior in cells. Bioengineering studies have found that breast cancer cells grown on a 3-D gel have enhanced cell replication and decreased organization as rigidity increases. These signals are probably coordinated by surface proteins that communicate with connective tissue, to regulate cell replication, death, and movement. However, very little is known about how stiffness or other physical characteristics of tissues contributes to cancer behavior in living animals.
Towards a better understanding of how tissue stiffness drives cancer, in a new paper published in PLoS Bio this week, Michael Pack, MD, associate professor of Medicine, Perelman School of Medicine, University of Pennsylvania, and colleagues, show that epithelial cells lining the intestine of zebrafish that carry an activating mutation of the smooth muscle myosin gene form protrusions called invadopodia that allow the cells to invade surrounding connective tissue. The epithelial cell protrusions form in response to non-regulated contractions in the surrounding smooth muscle cells. These contractions generate oxidative stress in the epithelial cells, which has been linked to invadopodia formation in human cancer cells.
Related Video
Credit: Christoph Seiler and Michael Pack, Perelman School of Medicine, University of Pennsylvania
The movie shows a segment of the mutant intestine (3.5 day old fish, lateral view of the intestine). The time lapse images were taken over about 6 - 8 hours. It is a transgenic mutant zebrafish that expressed the green fluorescent protein tagged to a peptide that binds to actin in epithelial cells. Normally actin lines the portion of the intestinal cells that are adjacent to the lumen of the intestinal tube. This is the bright green staining in the intestine. In the mutants, there also are small actin rich protrusions that appear within the plasma cell membrane on opposite side of the cells undergoing invasion. Invasive cells with these protrusions expand out in to the surrounding tissue stroma (arrows). The green structure on the top of the movie frame is the kidney duct. The intestine is below the kidney duct. The actin-rich protrusions are the invadopodia. Transcriptome profiles of the cells with invadopodia showed that genes responsive to reactive oxygen species were upregulated in young mutant fish.
The zebrafish mutant is a novel living model to study how physical characteristics of a tissue can induce cells to invade surrounding tissues, the first step in cancer metastasis.
Epithelial cells of the digestive tract and many other organs are separated from their underlying connective tissue cells by a thin layer of extracellular matrix called the basement membrane. During cell invasion, epithelial cells breach the basement membrane and invade the adjacent connective tissue where the organ’s blood vessels and lymphatic channels are located. Invasive cancer cells that are able to enter the blood vessels or lymphatics can migrate to distant tissues thus forming satellite tumors known as metastases.
An important question in cancer research is how invasive cells in living animals correctly localize the enzymes that degrade basement membrane proteins. Investigators have known for some time that many types of cancer cells accomplish this by forming specialized protrusions. It is not known, however, whether these invadopodia are required for cell invasion in living animals or what triggers their formation.
Researchers don’t even really know if invadopodia have a normal purpose in healthy tissue. Pack explains that their study was the first to show that invadopodia occur in living animals. This work in live zebrafish is the first direct evidence that invadopodia play a role in tissue cell invasion and identifies the physical signal that drives this process, which in turn, does so by inducing oxidative stress in the invasive cells.
Indeed, eliminating Tks5, a protein required for invadopodia formation in mammalian cells that helps generate reactive oxygen species, blocked formation of the protrusions and rescued mutant zebrafish from cell invasion.
Mouse studies along the same research lines as the zebrafish are planned. The zebrafish and mouse models under development could one day be used to screen potential drugs to stop formation of the errant invadopodia, thus preventing metastases at an early stage of their development. Supporting this idea, mutations in the human smooth muscle myosin genes are present in patients with colorectal cancer and are associated with cancer invasion.
In addition, the team's experiments also point to the possibility that humans who carry a single copy of smooth muscle mutations similar to the zebrafish mutation might inherit a disposition to cancer progression, if they develop a cancer independently of the mutation. The fish with one copy of the mutant gene develop normally but show cell invasion when exposed to drugs that cause oxidative stress, and the risk is greater in fish carrying oncogenes. "This is an interesting finding because oxidative stress is common in cancers and inflammatory conditions that predispose to cancer, such as ulcerative colitis," notes Pack.
Co-authors, all from Penn, are Christoph Seiler, Gangarao Davuluri, Joshua Abrams, Fitzroy J. Byfield, and Paul A. Janmey. The research was funded in part by the National Institute of Diabetes and Digestive and Kidney Diseases (Grant DK54942).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.